Alnylam Pharmaceuticals Inc (ALNY)
261.10
-3.37
(-1.27%)
USD |
NASDAQ |
Nov 14, 12:32
Alnylam Pharmaceuticals Research and Development Expense (Quarterly): 270.93M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 270.93M |
| June 30, 2024 | 294.14M |
| March 31, 2024 | 261.00M |
| December 31, 2023 | 272.14M |
| September 30, 2023 | 253.18M |
| June 30, 2023 | 248.53M |
| March 31, 2023 | 230.57M |
| December 31, 2022 | 262.04M |
| September 30, 2022 | 245.37M |
| June 30, 2022 | 205.71M |
| March 31, 2022 | 169.89M |
| December 31, 2021 | 229.05M |
| September 30, 2021 | 194.57M |
| June 30, 2021 | 182.64M |
| March 31, 2021 | 185.90M |
| December 31, 2020 | 168.47M |
| September 30, 2020 | 161.78M |
| June 30, 2020 | 155.00M |
| March 31, 2020 | 169.57M |
| December 31, 2019 | 201.30M |
| September 30, 2019 | 160.80M |
| June 30, 2019 | 163.89M |
| March 31, 2019 | 129.13M |
| December 31, 2018 | 131.04M |
| September 30, 2018 | 139.94M |
| Date | Value |
|---|---|
| June 30, 2018 | 137.58M |
| March 31, 2018 | 96.86M |
| December 31, 2017 | 117.77M |
| September 30, 2017 | 95.25M |
| June 30, 2017 | 90.63M |
| March 31, 2017 | 86.98M |
| December 31, 2016 | 105.01M |
| September 30, 2016 | 97.94M |
| June 30, 2016 | 83.17M |
| March 31, 2016 | 96.27M |
| December 31, 2015 | 82.84M |
| September 30, 2015 | 68.62M |
| June 30, 2015 | 67.01M |
| March 31, 2015 | 58.04M |
| December 31, 2014 | 55.55M |
| September 30, 2014 | 46.27M |
| June 30, 2014 | 44.67M |
| March 31, 2014 | 43.76M |
| December 31, 2013 | 32.11M |
| September 30, 2013 | 34.46M |
| June 30, 2013 | 24.22M |
| March 31, 2013 | 22.18M |
| December 31, 2012 | 21.68M |
| September 30, 2012 | 22.09M |
| June 30, 2012 | 21.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
155.00M
Minimum
Jun 2020
294.14M
Maximum
Jun 2024
218.09M
Average
217.38M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.598B |
| BridgeBio Pharma Inc | 114.70M |
| Biomarin Pharmaceutical Inc | 184.90M |
| Gilead Sciences Inc | 1.395B |
| Regeneron Pharmaceuticals Inc | 1.272B |